CA2542836A1 - Pharmaceutical formulations containing quetiapine - Google Patents
Pharmaceutical formulations containing quetiapine Download PDFInfo
- Publication number
- CA2542836A1 CA2542836A1 CA002542836A CA2542836A CA2542836A1 CA 2542836 A1 CA2542836 A1 CA 2542836A1 CA 002542836 A CA002542836 A CA 002542836A CA 2542836 A CA2542836 A CA 2542836A CA 2542836 A1 CA2542836 A1 CA 2542836A1
- Authority
- CA
- Canada
- Prior art keywords
- quetiapine
- dosage form
- hours
- weight
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960004431 quetiapine Drugs 0.000 title claims abstract 169
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title claims abstract 116
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 claims abstract 95
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 claims abstract 64
- 150000003839 salts Chemical class 0.000 claims abstract 58
- 239000000203 mixture Substances 0.000 claims abstract 21
- 238000000034 method Methods 0.000 claims abstract 13
- 239000012730 sustained-release form Substances 0.000 claims abstract 9
- 238000013268 sustained release Methods 0.000 claims abstract 5
- 239000003814 drug Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- -1 wax dosage forms Chemical compound 0.000 claims abstract 3
- 239000012738 dissolution medium Substances 0.000 claims 33
- 239000006186 oral dosage form Substances 0.000 claims 31
- 230000036470 plasma concentration Effects 0.000 claims 31
- 239000008199 coating composition Substances 0.000 claims 26
- 238000013270 controlled release Methods 0.000 claims 25
- 101100129500 Caenorhabditis elegans max-2 gene Proteins 0.000 claims 16
- 101100083446 Danio rerio plekhh1 gene Proteins 0.000 claims 15
- 239000000463 material Substances 0.000 claims 15
- 239000007909 solid dosage form Substances 0.000 claims 15
- 238000004090 dissolution Methods 0.000 claims 13
- 239000011159 matrix material Substances 0.000 claims 12
- 229960005197 quetiapine fumarate Drugs 0.000 claims 11
- 239000011248 coating agent Substances 0.000 claims 10
- 238000000576 coating method Methods 0.000 claims 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 8
- 230000001747 exhibiting effect Effects 0.000 claims 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 239000001993 wax Substances 0.000 claims 8
- 239000013543 active substance Substances 0.000 claims 7
- 229920001477 hydrophilic polymer Polymers 0.000 claims 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 7
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 239000008187 granular material Substances 0.000 claims 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 239000004203 carnauba wax Substances 0.000 claims 4
- 235000013869 carnauba wax Nutrition 0.000 claims 4
- 229940082483 carnauba wax Drugs 0.000 claims 4
- 229960001021 lactose monohydrate Drugs 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 229940069328 povidone Drugs 0.000 claims 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims 4
- 239000008109 sodium starch glycolate Substances 0.000 claims 4
- 239000004408 titanium dioxide Substances 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 235000010980 cellulose Nutrition 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 239000006057 Non-nutritive feed additive Substances 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 239000000155 melt Substances 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims 2
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 claims 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 239000005639 Lauric acid Substances 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 235000013871 bee wax Nutrition 0.000 claims 1
- 239000012166 beeswax Substances 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims 1
- 229940038472 dicalcium phosphate Drugs 0.000 claims 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229940043348 myristyl alcohol Drugs 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- 229940098780 tribehenin Drugs 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51346103P | 2003-10-21 | 2003-10-21 | |
| US60/513,461 | 2003-10-21 | ||
| PCT/US2004/034743 WO2005041935A1 (en) | 2003-10-21 | 2004-10-21 | Pharmaceutical formulations containing quetiapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2542836A1 true CA2542836A1 (en) | 2005-05-12 |
Family
ID=34549280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002542836A Abandoned CA2542836A1 (en) | 2003-10-21 | 2004-10-21 | Pharmaceutical formulations containing quetiapine |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20050158383A1 (https=) |
| EP (1) | EP1689367A1 (https=) |
| JP (1) | JP2007509155A (https=) |
| CN (1) | CN101005829A (https=) |
| CA (1) | CA2542836A1 (https=) |
| IS (1) | IS8460A (https=) |
| WO (1) | WO2005041935A1 (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| BRPI0606932A2 (pt) * | 2005-01-26 | 2009-07-28 | Elan Pharma Int Ltd | formulação, forma de dosagem, e, uso de uma quantidade terapeuticamente efetiva de uma formulação |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| DE602006004694D1 (de) * | 2006-01-05 | 2009-02-26 | Teva Pharma | Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen |
| EP1976487A2 (en) * | 2006-01-25 | 2008-10-08 | Astron Research Limited | Sustained release dosage form of phenothiazine derivatives containing channelizer |
| DE102006033723A1 (de) * | 2006-07-21 | 2008-01-24 | Bayer Technology Services Gmbh | Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe |
| CA2657202A1 (en) * | 2006-07-28 | 2008-01-31 | Farmaprojects, S.A. | Extended release pharmaceutical formulation of metoprolol and process for its preparation |
| GB0618879D0 (en) * | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| WO2008052354A1 (en) * | 2006-11-03 | 2008-05-08 | University Of Saskatchewan | Method of treating demyelination diseases |
| PT103884A (pt) * | 2006-11-17 | 2008-05-19 | Astrazeneca Ab | Composições de libertação prolongada e métodos para a sua preparação |
| ATE480227T1 (de) * | 2007-02-14 | 2010-09-15 | Lesvi Laboratorios Sl | Pharmazeutische zusammensetzungen mit quetiapinfumarat |
| EP2131817A2 (en) * | 2007-03-09 | 2009-12-16 | Synthon B.V. | Pharmaceutical composition of quetiapine fumarate |
| EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
| US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US8865692B2 (en) * | 2007-11-13 | 2014-10-21 | Meritage Pharma, Inc | Compositions for the treatment of gastrointestinal inflammation |
| US20090149433A1 (en) | 2007-11-13 | 2009-06-11 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| US20090220593A1 (en) * | 2008-01-29 | 2009-09-03 | Gulati Inder | Extended release dosage forms of quetiapine |
| EP2268283A2 (en) * | 2008-03-12 | 2011-01-05 | Dexcel Ltd. | Oral modified-release formulations containing thiazepines |
| WO2010001413A2 (en) * | 2008-07-01 | 2010-01-07 | Lupin Limited | Sustained release pharmaceutical compositions comprising quetiapine |
| RS53866B1 (sr) | 2008-07-16 | 2015-08-31 | Richter Gedeon Nyrt. | Farmaceutske formulacije koje sadrže ligande dopaminskih receptora |
| EP2299983A4 (en) * | 2008-07-24 | 2012-10-10 | Handa Pharmaceuticals Llc | ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED |
| DE202009018024U1 (de) | 2008-08-01 | 2010-12-09 | Krka Tovarna Zdravil, D.D., Novo Mesto | Quetiapin-Zusammensetzung |
| EP2153834A3 (en) * | 2008-08-07 | 2010-02-24 | Farmaprojects, S.A. | Extended release pharmaceutical compositions comprising quetiapine salts |
| CA2736119C (en) * | 2008-09-04 | 2016-08-23 | Farnam Companies, Inc. | Chewable sustained release formulations |
| DE102008046650A1 (de) * | 2008-09-10 | 2010-03-11 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Quetiapin enthaltende Retardtablette |
| WO2010066342A1 (en) * | 2008-11-26 | 2010-06-17 | Krka | Quetiapine composition |
| US20110280938A1 (en) * | 2009-01-05 | 2011-11-17 | Torrent Pharmaceuticals Limited | Sustained release pharmaceutical composition of quetiapine and process for preparation thereof |
| WO2010089259A2 (en) | 2009-02-04 | 2010-08-12 | Woerwag R&D Gmbh | Sustained release composition containing quetiapine |
| EP2233130A1 (en) * | 2009-03-23 | 2010-09-29 | Genepharm (Europe) Trading Limited | A sustained release oral composition of an antipsychotic agent |
| WO2010144865A2 (en) * | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| US8715699B2 (en) | 2009-12-31 | 2014-05-06 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| WO2011103718A1 (zh) * | 2010-02-26 | 2011-09-01 | 上海沪美医药科技有限公司 | 一种含有喹硫平的控（缓）释制剂及其制备方法和用途 |
| MX339408B (es) * | 2010-03-09 | 2016-05-24 | Alkermes Pharma Ireland Ltd | Composiciones farmaceuticas entericas resistentes al alcohol. |
| WO2011112657A1 (en) | 2010-03-11 | 2011-09-15 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
| ES2645015T3 (es) * | 2010-04-07 | 2017-12-01 | Kemin Industries, Inc. | Micropartículas para la administración oral en animales |
| WO2011132008A2 (en) | 2010-04-22 | 2011-10-27 | EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság | Controlled release pharmaceutical composition |
| CA2705685A1 (en) * | 2010-05-27 | 2011-11-27 | Pharmascience Inc. | Pharmaceutical dosage form containing an antipsychotic agent |
| WO2011154118A1 (en) | 2010-06-07 | 2011-12-15 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Quetiapine prolonged-release tablets |
| DE102010033527A1 (de) | 2010-08-05 | 2012-02-09 | Acino Pharma Ag | Quetiapin-Tabletten |
| TR201008261A1 (tr) * | 2010-10-08 | 2012-04-24 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Kontrollü salım gerçekleştiren ketiapin formülasyonları |
| CN102525988B (zh) * | 2011-01-04 | 2016-01-06 | 北京天衡药物研究院 | 富马酸喹硫平缓释片 |
| AT511581A1 (de) * | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | Orale retardierende formulierung |
| DE102011115690A1 (de) | 2011-10-11 | 2013-04-11 | Acino Pharma Ag | Quetiapin enthaltende Formulierungen |
| WO2013100879A1 (en) * | 2011-12-27 | 2013-07-04 | Mahmut Bilgic | Pharmaceutical compositions comprising quetiapine |
| CN103211794A (zh) * | 2012-01-18 | 2013-07-24 | 北京天衡药物研究院 | 富马酸喹硫平膜控缓释微丸胶囊 |
| US8912197B2 (en) | 2012-08-20 | 2014-12-16 | Forest Laboratories Holdings Ltd. | Crystalline form of carbamoyl-cyclohexane derivatives |
| PL2822541T3 (pl) | 2012-09-10 | 2019-02-28 | Pharmathen S.A. | Kompozycja farmaceutyczna zawierająca nietypowy środek przeciwpsychotyczny i sposób jej wytwarzania |
| WO2014155387A1 (en) * | 2013-03-24 | 2014-10-02 | Tushar Patel | Extended release dosage forms of quetiapine salts |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015023704A1 (en) * | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| GB201420311D0 (en) | 2014-11-14 | 2014-12-31 | Bio Images Drug Delivery Ltd | Pharmaceutical processing |
| GB201420306D0 (en) | 2014-11-14 | 2014-12-31 | Bio Images Drug Delivery Ltd | Compositions |
| GB201420300D0 (en) * | 2014-11-14 | 2014-12-31 | Bio Images Drug Delivery Ltd | Tablet |
| CN104523600A (zh) * | 2014-11-21 | 2015-04-22 | 哈尔滨圣吉药业股份有限公司 | 一种富马酸喹硫平缓释微丸及其制备方法 |
| CN104546800A (zh) * | 2015-01-07 | 2015-04-29 | 万特制药(海南)有限公司 | 一种富马酸喹硫平缓释胶囊及其制备方法 |
| RU2588840C1 (ru) * | 2015-03-26 | 2016-07-10 | Общество с ограниченной ответственностью ООО "ВАЛЕНТА-ИНТЕЛЛЕКТ" | Таблетки кветиапина с пролонгированным высвобождением и способ их получения |
| WO2017106812A1 (en) * | 2015-12-19 | 2017-06-22 | First Time Us Generics Llc | Soft-chew tablet pharmaceutical formulations |
| US20190022013A1 (en) | 2015-12-19 | 2019-01-24 | First Time Us Generics Llc | Soft-chew tablet pharmaceutical formulations |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
| WO2020025579A1 (en) * | 2018-07-31 | 2020-02-06 | Medichem, S.A. | Solid dosage form of quetiapine fumarate |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| EP4213817A1 (en) | 2020-09-21 | 2023-07-26 | Sun Pharmaceutical Industries Limited | Multi-particulate pharmaceutical composition of quetiapine |
| US12251208B2 (en) * | 2020-11-30 | 2025-03-18 | International Business Machines Corporation | Time controlled medication |
| AU2023365355A1 (en) * | 2022-10-19 | 2025-05-29 | Vitakey Inc. | Formulated food products |
| CN120114403B (zh) * | 2025-03-12 | 2025-12-02 | 上海国创医药股份有限公司 | 一种富马酸喹硫平缓释组合物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| JP3628401B2 (ja) * | 1995-11-09 | 2005-03-09 | 信越化学工業株式会社 | 無溶媒腸溶性コーティング剤された腸溶性製剤 |
| US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| PT1140012E (pt) * | 1998-12-17 | 2004-05-31 | Alza Corp | Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas |
| WO2003039514A1 (en) * | 2001-10-18 | 2003-05-15 | Verion Inc. | Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods |
| US20030158254A1 (en) * | 2002-01-24 | 2003-08-21 | Xenoport, Inc. | Engineering absorption of therapeutic compounds via colonic transporters |
-
2004
- 2004-10-21 JP JP2006536758A patent/JP2007509155A/ja active Pending
- 2004-10-21 US US10/970,850 patent/US20050158383A1/en not_active Abandoned
- 2004-10-21 CN CNA2004800383272A patent/CN101005829A/zh active Pending
- 2004-10-21 EP EP04795849A patent/EP1689367A1/en not_active Withdrawn
- 2004-10-21 WO PCT/US2004/034743 patent/WO2005041935A1/en not_active Ceased
- 2004-10-21 CA CA002542836A patent/CA2542836A1/en not_active Abandoned
-
2006
- 2006-05-11 IS IS8460A patent/IS8460A/is unknown
- 2006-11-09 US US11/595,758 patent/US20070244093A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005041935A1 (en) | 2005-05-12 |
| US20070244093A1 (en) | 2007-10-18 |
| EP1689367A1 (en) | 2006-08-16 |
| IS8460A (is) | 2006-05-11 |
| CN101005829A (zh) | 2007-07-25 |
| JP2007509155A (ja) | 2007-04-12 |
| US20050158383A1 (en) | 2005-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1715856B1 (en) | Atomoxetine formulations | |
| US20070244093A1 (en) | Quetiapine formulations | |
| EP2066325B1 (en) | Pharmaceutical compositions of aripiprazole | |
| US20050232990A1 (en) | Donepezil formulations | |
| US20050191349A1 (en) | Galantamine formulations | |
| US20050163858A1 (en) | Ziprasidone formulations | |
| US20050163842A1 (en) | Rosiglitazone and metformin formulations | |
| US20050163837A1 (en) | Rosiglitazone formulations | |
| US20050163843A1 (en) | Alprazolam formulations | |
| CA2683692A1 (en) | Pharmaceutical compositions | |
| US20060039975A1 (en) | Paroxetine formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20131022 |